Statins reduce mortality in sepsis
Statin therapy reduces the risk of death significantly for patients with sepsis, researchers reported on June 6, 2025 in Frontiers in Immunology. As background, the authors noted that… read more.
Statin therapy reduces the risk of death significantly for patients with sepsis, researchers reported on June 6, 2025 in Frontiers in Immunology. As background, the authors noted that… read more.
Hympavzi (marstacimab) from Pfizer has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat haemophilia A or B in adult and paediatric patients…. read more.
Nurix Therapeutics, Inc. announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia… read more.
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower… read more.
Hydroxyurea therapy, a standard treatment for children with sickle cell disease (SCD), remains effective over the long term for reducing emergency department visits and hospital days among pediatric… read more.
NICE (UK): burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in… read more.
Novo Nordisk announced that the FDA approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients… read more.
Roche announced that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology (ASH) Annual Meeting &… read more.
Pfizer has decided to terminate the development and commercialization of its hemophilia B gene therapy fidanacogene elaparvovec (marketed as Beqvez) globally, resulting in the withdrawal of its regulatory… read more.
In patients with ACS (acute coronary syndrome) who have undergone DES (drug-eluting stent) implantation, de-escalating DAPT (dual antiplatelet therapy) to ticagrelor monotherapy resulted in a lower risk for… read more.
A new set of guidelines has been developed to assist with the diagnosis and expert management of serious blood cancers in pregnancy. About 12.5 pregnancies per 100,000 are… read more.
AstraZeneca PLC’s anticoagulant reversal agent Andexxa (andexanet) will not convert to full approval, after the FDA issued a complete response letter for the supplemental biologics license application. The… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.